- The 2025 MGP Pass Rate Numbers
- What the Numbers Actually Mean for Candidates
- Why the Scaled Score of 500 Matters More Than the Percentage
- Exam Structure Behind the Numbers
- Domains Most Likely to Cost You Points
- How Eligibility Affects Who Even Sits the Exam
- A Domain-Weighted Prep Timeline
- Frequently Asked Questions
- In 2025, 50 of 56 total examinees passed the MGP exam, reported by ABPath as 89%.
- First-time examinees passed at a higher rate: 45 of 49, reported as 92%.
- Passing depends on a scaled score of 500, not a fixed raw percentage of correct answers.
- Solid Tumors (11%), Inherited Diseases (10%), and Hematopathology (9%) carry the heaviest blueprint weight.
The 2025 MGP Pass Rate Numbers
If you're researching Certification in Pathology: Molecular Genetic Pathology (MGP), you've probably already seen conflicting pass rate figures floating around for exams that share the same three-letter acronym. To be clear, this article covers only the joint ABPath/ABMGG subspecialty certification exam in molecular genetic pathology - not any other credential that happens to use "MGP" as shorthand.
According to ABPath's own reporting, the 2025 administration produced the following results:
- Overall pass rate: 50 of 56 examinees passed, reported as 89%.
- First-time examinee pass rate: 45 of 49 first-time takers passed, reported as 92%.
Those are the only pass rate figures published for this specific exam cycle, and they are the only numbers this article will use. If you see a study source citing different figures for "MGP," it is almost certainly describing a different certification entirely.
What the Numbers Actually Mean for Candidates
The gap between the overall pass rate (89%) and the first-time pass rate (92%) is worth sitting with. First-time examinees outperformed the overall pool, which includes repeat test-takers. That pattern suggests the exam rewards focused, front-loaded preparation rather than a strategy of "sit it once to see the format, then retake."
Because MGP candidates are already board-certified or board-eligible physicians who have completed a full ACGME-accredited fellowship year, the population sitting this exam is not a general audience - it is a small group of highly trained subspecialists. That context matters: a pass rate in the high 80s to low 90s percent range, in a cohort this experienced, still implies that the exam has real discriminating power across its 17 content domains, particularly in areas where day-to-day fellowship exposure varies by program.
For a full breakdown of how demanding the exam is relative to other pathology subspecialty boards, see How Hard Is the MGP Exam? Complete Difficulty Guide 2026.
Why the Scaled Score of 500 Matters More Than the Percentage
One detail that gets lost in pass rate discussions: ABPath does not publish a raw percentage-correct threshold for passing. The passing standard is a scaled score of 500. That means the 89%/92% figures describe outcomes, not the scoring mechanism itself.
Scaled scoring adjusts for the difficulty of the specific question set a candidate receives, which matters because the 2026 exam blueprint spreads 245 questions across six sections. Two candidates could answer a different mix of questions correctly and both land at or above 500, depending on item difficulty. This is explained in more depth in MGP Passing Score 2026: Exactly What You Need to Pass.
Key Takeaway
Don't study to "get 70% right." Study to minimize weak spots across all 17 domains, since scaled scoring rewards broad competence more than it rewards being excellent in two domains and shaky in the rest.
Exam Structure Behind the Numbers
Understanding exam mechanics helps explain why preparation quality - not just knowledge volume - drives the pass rate. The 2026 MGP exam is a computer-based, single-best-answer multiple-choice test that also incorporates written/practical material. Key logistics:
- 245 questions across six sections
- 6 hours 34 minutes of active testing time
- 9 hours 4 minutes total scheduled time, including instructions, survey, and breaks
- Administered in person at Pearson VUE Professional Centers - this is not a remotely proctored home exam
- 2026 initial application/examination fee: USD 2,100, which includes a USD 200 nonrefundable administrative fee
A nearly nine-hour scheduled day is a significant endurance test on top of a content test. Candidates who haven't simulated that duration during practice sometimes lose points late in the exam simply from fatigue, not knowledge gaps. For the full fee mechanics and what's included in that USD 2,100 figure, see MGP Certification Cost 2026: Complete Pricing Breakdown, and for exact registration windows, check MGP Exam Dates 2026: Testing Windows, Deadlines & Scheduling.
Domains Most Likely to Cost You Points
The 2026 blueprint allocates approximate weight across 17 domains. The heaviest three are where most study time should concentrate, but they're also where subtle question-writing (distinguishing germline vs. somatic findings, or interpreting a karyotype against a pedigree) trips up otherwise strong candidates.
Domain 10: Solid Tumors (11%)
The single largest domain on the blueprint. Expect questions built around sequence and array findings tied to specific tumor types, requiring you to connect a molecular result to clinical significance rather than just recall a mutation name.
- Practice interpreting variant reports in the context of tumor classification
- Know which alterations are prognostic vs. purely diagnostic
Domain 8: Inherited Diseases (10%)
This domain leans heavily on pedigree analysis and distinguishing inheritance patterns from incidental findings.
- Practice reading multi-generation pedigrees quickly under time pressure
- Differentiate germline findings from somatic mosaicism scenarios
Domain 11: Hematopathology (9%)
Questions here often combine molecular data with morphologic or clinical context, testing integration rather than isolated recall.
- Correlate cytogenetic/molecular findings with hematologic disease categories
- Review common laboratory-method pitfalls specific to blood and marrow specimens
Beyond the top three, don't neglect the mid-weighted domains - Normal Structure and Function, Molecular Genetic Principles, and Assay Performance and Validation are each weighted 7% and collectively account for more of the exam than Solid Tumors alone. A domain-by-domain walkthrough of all 17 areas, including the smaller but still scored categories like Histocompatibility (2%) and Management and Informatics-General (3%), is available in MGP Exam Domains 2026: Complete Guide to All 17 Content Areas.
| Domain | Weight | Common Question Focus |
|---|---|---|
| Solid Tumors | 11% | Sequence/array findings tied to tumor classification |
| Inherited Diseases | 10% | Pedigree interpretation, inheritance patterns |
| Hematopathology | 9% | Molecular findings integrated with hematologic disease |
| Normal Structure and Function | 7% | Baseline anatomy/physiology as a foundation for abnormal findings |
| Molecular Genetic Principles | 7% | Core mechanisms underlying assay interpretation |
| Assay Performance and Validation | 7% | Validation study design, performance characteristics |
How Eligibility Affects Who Even Sits the Exam
Because MGP is a joint subspecialty of ABPath and ABMGG, eligibility itself filters the candidate pool before pass rate data even comes into play. To sit the exam, a candidate generally needs qualifying primary ABPath certification (AP/CP, AP, or CP) or eligible ABMGG physician certification, plus 12 months of ACGME-accredited Molecular Genetic Pathology fellowship training, along with standard medical education, licensure, and training-verification requirements.
This means every examinee in the 2025 cohort of 56 had already cleared a demanding fellowship and a prior board certification. The relatively strong pass rates reflect a self-selected, highly trained group - not a broad general test-taking population. If you're still mapping out whether you meet the fellowship and licensure prerequisites, review MGP Requirements 2026: Eligibility, Prerequisites & How to Qualify before assuming the pass rate applies equally to your situation.
A Domain-Weighted Prep Timeline
Generic study techniques (spaced repetition, timed blocks) only help if they're mapped to the actual blueprint weight. Here's a sample allocation built around domain size rather than a generic weekly template:
Solid Tumors + Inherited Diseases
- Work through sequence/array case examples for common solid tumor alterations
- Drill pedigree interpretation until pattern recognition is automatic
Hematopathology + Inherited Cancer Syndromes
- Integrate molecular findings with hematologic disease categories
- Review cancer syndrome genetics alongside somatic vs. germline distinctions
Molecular Principles, Techniques, Assay Validation
- Reinforce underlying lab science that supports every clinical scenario question
- Practice validation study design questions specifically
Quality, Ethics/Legal, Pharmacogenetics, Infectious Disease, plus smaller domains
- Cover lower-weighted but still-tested domains: Identity Testing, Histocompatibility, Informatics
- Run full-length timed practice sessions matching the 6-hour-34-minute active testing block
For a structured, first-attempt-focused version of this plan with more detail on pacing and question strategy, see MGP Study Guide 2026: How to Pass on Your First Attempt. And if you want a compact reference to keep the domain weights and key facts in front of you during final review, MGP Cheat Sheet 2026: One-Page Review of Must-Know Facts condenses this article's numbers into a single page.
Practicing with timed, domain-weighted question sets on our practice test platform before exam day is one of the more direct ways to rehearse the pacing this exam demands, since 245 questions in roughly six and a half hours leaves little room for getting stuck on any single item.
Frequently Asked Questions
ABPath reported that 50 of 56 total examinees passed (89%), and 45 of 49 first-time examinees passed (92%) in the 2025 administration.
No. Passing depends on reaching a scaled score of 500 set by ABPath, not a fixed raw percentage of questions answered correctly.
The overall rate includes repeat examinees, while the first-time rate (92%) reflects only candidates testing for the first time, which suggests focused initial preparation tends to perform better.
Since specific per-domain pass rates aren't published, prioritize by blueprint weight: Solid Tumors (11%), Inherited Diseases (10%), and Hematopathology (9%) carry the most points and deserve the most study time.
Partly. Every examinee already holds qualifying ABPath or ABMGG certification and completed 12 months of ACGME-accredited MGP fellowship training, so the tested population is already highly selected before the pass rate is calculated.